Tools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?

被引:173
作者
Hemingway, Janet [1 ]
Shretta, Rima [2 ]
Wells, Timothy N. C. [3 ]
Bell, David [4 ]
Djimde, Abdoulaye A. [5 ]
Achee, Nicole [6 ]
Qi, Gao [7 ]
机构
[1] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England
[2] Univ Calif San Francisco, Malaria Eliminat Initiat, Global Hlth Grp, San Francisco, CA 94143 USA
[3] Med Malaria Venture, Geneva, Switzerland
[4] Global Good Fund & Intellectual Ventures Lab, Bellevue, WA USA
[5] Univ Bamako, Malaria Res & Training Ctr, Dept Epidemiol Parasit Dis, Bamako, Mali
[6] Univ Notre Dame, Eck Inst Global Hlth, Dept Biol Sci, Notre Dame, IN 46556 USA
[7] Jiangsu Inst Parasit Dis, Wuxi, Jiangsu, Peoples R China
基金
比尔及梅琳达.盖茨基金会;
关键词
G6PD DEFICIENCY; PRIMAQUINE; POPULATIONS;
D O I
10.1371/journal.pbio.1002380
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Progress made in malaria control during the past decade has prompted increasing global dialogue on malaria elimination and eradication. The product development pipeline for malaria has never been stronger, with promising new tools to detect, treat, and prevent malaria, including innovative diagnostics, medicines, vaccines, vector control products, and improved mechanisms for surveillance and response. There are at least 25 projects in the global malaria vaccine pipeline, as well as 47 medicines and 13 vector control products. In addition, there are several next-generation diagnostic tools and reference methods currently in development, with many expected to be introduced in the next decade. The development and adoption of these tools, bolstered by strategies that ensure rapid uptake in target populations, intensified mechanisms for information management, surveillance, and response, and continued financial and political commitment are all essential to achieving global eradication.
引用
收藏
页数:14
相关论文
共 41 条
[1]
A Research Agenda for Malaria Eradication: Drugs [J].
Alonso, Pedro L. ;
Djimde, Abdoulaye ;
Kremsner, Peter ;
Magill, Alan ;
Milman, Jessica ;
Najera, Jose ;
Plowe, Christopher V. ;
Rabinovich, Regina ;
Wells, Timothy ;
Yeung, Shunmay .
PLOS MEDICINE, 2011, 8 (01)
[2]
[Anonymous], 2015, GLOB PORTF ANT MED 1
[3]
[Anonymous], 2006, MAL VACC TECHN ROADM
[4]
[Anonymous], 2015, LANCET, V385, P1591, DOI DOI 10.1016/S0140-6736(15)60774-7
[5]
[Anonymous], 2014, WORLD MAL REP 2014
[6]
[Anonymous], 2014, SURV SYST FAC MAL EL
[7]
[Anonymous], 2012, SAF EFF SINGL DOS PR
[8]
Primaquine: the risks and the benefits [J].
Ashley, Elizabeth A. ;
Recht, Judith ;
White, Nicholas J. .
MALARIA JOURNAL, 2014, 13
[9]
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria [J].
Baird, Kevin .
PATHOGENS AND GLOBAL HEALTH, 2015, 109 (03) :93-106
[10]
Designing the next generation of medicines for malaria control and eradication [J].
Burrows, Jeremy N. ;
van Huijsduijnen, Rob Hooft ;
Moehrle, Joerg J. ;
Oeuvray, Claude ;
Wells, Timothy N. C. .
MALARIA JOURNAL, 2013, 12